The leader peptide of a human rec. MnSOD as molecular carrier which delivers high amounts of cisplatin into tumor cells inducing a fast apoptosis in vitro

International Journal of Cancer

Volumn 128, Issue 2, 2011, Pages 453-459

  Borrelli, Antonella ^a   Schiattarella, Antonietta ^a   Mancini, Roberto ^a   Morelli, Franco ^b   Capasso, Clemente ^c   De Luca, Viviana ^c   Gori, Enrico ^d   Mancini, Aldo ^a  

^a Department of Molecular Biology and Viral Oncogenesis NCI of Naples ^*  (Italy)

^b CNR   (Italy)

^c INSTITUTE OF PROTEIN BIOCHEMISTRY   (Italy)

^d UNIVERSITY OF UDINE   (Italy)

Author keywords

cisplatin; leader peptide; molecular carrier; rMnSOD

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN BAX; RECOMBINANT MANGANESE SUPEROXIDE DISMUTASE LEADER PEPTIDE CISPLATIN CONJUGATE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CISPLATIN; DRUG CARRIERS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; HUMANS; NEOPLASMS; POLYMERASE CHAIN REACTION; PROTEIN SORTING SIGNALS; SPECTROPHOTOMETRY, ATOMIC; SUPEROXIDE DISMUTASE;

EID: 78649571038     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25334     Document Type: Article

References (27)

1. Skipper HE, Perry S,. Kinetics of normal and leukemic leukocyte population and relevance to chemotherapy. Cancer Res 1970; 30: 1883-97.
2. Collins VP, Loeffler RK, Tivey H,. Observation on growth rate of human tumors. Am J Roentgenol 1956; 76: 988-1000.
3. Stockdale FE,. Cancer growth and chemotherapy. In:, Rubinstein E, Federman DD, eds. Scientific American medicine. Oncology. New York: Scientific American, 1987. pp. 1-13.
4. Richard D, Brokx S, Bisland K, Gariépy J,. Designing peptide-based scaffolds as drug delivery vehicles. J Control Release 2002; 78: 115-23.
5. Mayer LD, Hope MJ, Cullis PR,. Vesicles of variable sizes produced by a rapid extrusion procedure. Biochem Biophys Acta 1986; 858: 161-8.
6. Ostro MJ,. Liposomes. New York: Marcel Dekker Inc., 1983.
7. Ostro MJ,. Liposomes. Sci Am 1987; 256: 102-11.
8. Gregoriadis G,. The carrier potential of liposomes in biology and medicine. N Engl J Med 1976; 295: 704-10.
9. Weinstein JN,. Liposomes in the diagnosis and treatment of cancer. In:, Ostro, ed. Liposomes from biophysics to therapeutics.
10. Aris SM, Gewirtz DA, Ryan JJ, Knott KM, Farrell NP,. Promotion of DNA strand breaks, interstrand cross-links and apoptotic cell death in A2780 human ovarian cancer cells by transplatinum planar amine complexes. Biochem Pharmacol 2007; 73: 1749-57.
11. Wangila GW, Nagothu KK, Steward R, III, Bhatt R, Iyere PA, Willingham WM, Sorenson JR, Shah SV, Portilla D,. Prevention of cisplatin-induced kidney epithelial cell apoptosis with a Cu superoxide dismutase-mimetic [copper 2 II (3,5ditertiarybutylsalicylate) 4 (ethanol)4]. Toxicol In Vitro 2006; 20: 1300-12.
12. Harte RJ, Matthews JC, O'Reilly SM, Tilsley DW, Osman S, Brown G, Luthra SJ, Brady F, Jones T, Price PM,. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl- L -aspartate, folinic acid, and interferon alpha. Clin Oncol 1999; 17: 1580-8.
13. Yoshikawa R, Kusunoki M, Yanagi H, Noda M, Furuyama JI, Yamamura T, Hashimoto-Tamaoki T,. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res 2001; 61: 1029-37.
14. Bay RZ, Wu Y, Liu Q, Xie K, Wei YQ, Wang YS, Liu K, Luo Y, Su JM, Hu B, Liu JY, Li Q, et al,. Suppression of lung cancer in murine model: treated by combination of recombinant human endostatin adenovirus with low-dose cisplatin. J Exp Clin Cancer Res 2009; 5: 28-31.
15. Swenson CE, Popescu MC, Ginsberg RS,. Preparation and use of liposomes in the treatment of microbial infections. Crit Rev Microbiol 1988; 15 (Suppl 1): S1-S31.
16. Mancini A, Borrelli A, Schiattarella A, Fasano S, Occhiello A, Pica A, Tommasino M, Nüesch JPF, Rommelaere J,. Tumor suppressive activity of a variant isoform of Mn superoxide dismutase released by a human liposarcoma cell line. Int J Cancer 2006; 119: 932-43.
17. Borrelli A, Schiattarella A, Mancini R, Morrica B, Cerciello V, Mormile M, d'Alesio V, Bottalico L, Morelli F, D'Armiento M, D'Armiento FP, Mancini A,. A recombinant MnSOD is radioprotective for normal cells and radiosensitizing for tumor cells. Free Radic Biol Med 2009; 46: 110-16.
18. Mancini A, Borrelli A, Schiattarella A, Aloj L, Aurilio M, Morelli F, Pica A, Occhiello A, Lorizio R, Mancini R, Sica A, Mazzarella L, et al,. Biophysical and biochemical characterization of a liposarcoma derived recombinant MnSOD protein acting as anticancer agent. Int J Cancer 2008; 123: 2684-95.
19. Stewart JM, Young JD,. Solid phase peptide synthesis. Rockford, IL: Pierce Chemical, 1984.
20. Welz B,. Atomic absorption spectrometry. Verlag Chemie, 1983.
21. Chomczynski P, Sacchi N,. The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. Nat Protoc 2006; 1: 581-5.
22. Welch BL,. The generalization of student's problem when several different population variances are involved. Biometrika 1947; 34: 28-35.
23. Sawilowsky SS, Fermat, Schubert, Einstein, Behrens-Fisher,. The probable difference between two means when σ1 = σ2: the Behrens-Fisher problem. J Mod Appl Stat Methods 2002; 1: 461-72.
24. Harte RJ, Matthews JC, O'Reilly SM, Tilsley DW, Osman S, Brown G, Luthra SJ, Brady F, Jones T, Price PM,. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl- L -aspartate, folinic acid, and interferon alfa. Clin Oncol 1999; 17: 1580-8.
25. Lamya A,. Therapeutic drug monitoring of cancer chemotherapy. 2007; 13: 207-21.
26. Hon YY, Evans WE,. Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach. Clin Chem 1998; 44: 388-400.
27. Keller K, Meyer-Estorf G, Beck OA, Hochrein H,. Correlation between serum concentration and pharmacological effect on atrioventicular conduction time of the antiarhythmic drug. Eur J Clin Pharmacol 2004; 13: 1432-41.